Lisanti Capital Growth’s Charles River Laboratories CRL Stock Holding History

Lisanti Capital Growth’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-8,845	Closed	-$3.65M	–	123
2021 Q3	$3.65M	Buy	8,845 +1,725	+24%	+$716K	0.54%	76
2021 Q2	$2.63M	Sell	7,120 -10,890	-60%	-$3.64M	0.33%	107
2021 Q1	$5.22M	Buy	18,010 +9,185	+104%	+$2.55M	0.67%	66
2020 Q4	$2.21M	Hold	8,825	–	–	0.31%	99
2020 Q3	$2M	Buy	8,825 +2,290	+35%	+$475K	0.37%	85
2020 Q2	$1.14M	Buy	+6,535	New	+$1.04M	0.23%	106

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lisanti Capital Growth's CRL Position: Q4 2021 in Review

Lisanti Capital Growth sold out of Charles River Laboratories (CRL) in Q4 2021, closing a stake of 8,845 shares — an estimated $3.65M sold.

Lisanti Capital Growth first reported a position in CRL in Q2 2020 and held it in 6 quarters. The position peaked at $5.22M in Q1 2021. 707 funds tracked by Wall St. Rank hold CRL as of Q4 2021.

Lisanti Capital Growth reported no remaining Charles River Laboratories position as of Q4 2021 after selling out during the quarter.
Lisanti Capital Growth sold 8,845 Charles River Laboratories shares in Q4 2021, an estimated $3.65M.
Lisanti Capital Growth first reported a position in Charles River Laboratories in Q2 2020 and held it in 6 quarters.
Lisanti Capital Growth's Charles River Laboratories position peaked at $5.22M in Q1 2021.
707 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2021.

Based on Lisanti Capital Growth's 13F filing for Q4 2021, filed 4 Feb 2022.